Crestwood Advisors Group LLC Invests $41,000 in ImmunityBio, Inc. (NASDAQ:IBRX)

Crestwood Advisors Group LLC bought a new position in shares of ImmunityBio, Inc. (NASDAQ:IBRX) during the fourth quarter, according to its most recent disclosure with the Securities & Exchange Commission. The fund bought 16,200 shares of the company’s stock, valued at approximately $41,000.

A number of other institutional investors and hedge funds also recently modified their holdings of IBRX. Stephens Inc. AR acquired a new stake in shares of ImmunityBio during the fourth quarter worth $26,000. Captrust Financial Advisors acquired a new position in ImmunityBio during the third quarter valued at $41,000. Mutual Advisors LLC acquired a new position in ImmunityBio during the fourth quarter valued at $41,000. Virtu Financial LLC acquired a new position in ImmunityBio during the third quarter valued at $51,000. Finally, New York State Common Retirement Fund raised its position in ImmunityBio by 62.8% during the fourth quarter. New York State Common Retirement Fund now owns 32,418 shares of the company’s stock valued at $83,000 after buying an additional 12,500 shares during the period. 8.58% of the stock is owned by institutional investors and hedge funds.

ImmunityBio Price Performance

Shares of IBRX stock opened at $3.00 on Thursday. ImmunityBio, Inc. has a fifty-two week low of $2.28 and a fifty-two week high of $10.53. The stock’s 50-day moving average is $3.00 and its two-hundred day moving average is $3.76. The firm has a market cap of $2.09 billion, a P/E ratio of -3.26 and a beta of 0.94.

Wall Street Analyst Weigh In

Several research analysts recently weighed in on the company. D. Boral Capital reissued a “buy” rating and set a $30.00 price target on shares of ImmunityBio in a research report on Friday, February 14th. BTIG Research assumed coverage on ImmunityBio in a research report on Friday, January 10th. They set a “buy” rating and a $6.00 price target on the stock.

About ImmunityBio

ImmunityBio, Inc, a clinical-stage biotechnology company, engages in developing therapies and vaccines that bolster the natural immune system to defeat cancers and infectious diseases. Its platforms for the development of biologic product candidates include antibody-cytokine fusion proteins; DNA, RNA, and recombinant protein vaccines; and cell therapies.